Bridging Pharmacokinetics & Pharmacodynamics to Enhance the Pre-Clinical Efficacy of Degrader-Loaded ADCs Targeting SMARCA &CDK9 for Drug Development Optimisation
Time: 11:15 am
day: Day 1, Track 2, AM
Details:
- Exploring the pharmacokinetic and pharmacodynamic challenges unique to SMARCA and CDK9 targets, focusing on degradation thresholds required to maximise therapeutic efficacy
- Examining the role of linker stability and release mechanisms in ADCs carrying degrader payloads, aiming to achieve controlled, targeted delivery of degraders to tumour cells
- Assessing how linker and payload characteristics influence absorption, distribution, metabolism, and excretion (ADME) profiles, and fine-tuning bioavailability to ensure a balanced therapeutic index and enhanced safety profile
